-
Jan 17, 2025 | 
jamanetwork.com | Robert M. Califf |Ali Abbasi |Lesley H. Curtis
Consequences and Opportunities From Poor Uptake of COVID Vaccinations Despite Strong Evidence As we enter the winter season of viral illnesses, infections with SARS-CoV-2 (the virus that causes COVID-19), respiratory syncytial virus, and influenza are each on the rise, and there is increasing concern for a pandemic of avian influenza (ie, bird flu) given the enormous animal reservoirs for the virus.
-
Nov 20, 2024 | 
jamanetwork.com | Ali Abbasi |Hannah Decker |Elizabeth C. Wick
The Quality of Evidence Supporting Clinical Practice Guidelines in General Surgery: A Meta-Analysis
Clinical practice guidelines can help patients and physicians make decisions using the best available evidence.
-
Nov 15, 2024 | 
jamanetwork.com | Joshua M. Hauser |Rita F. Redberg |Ali Abbasi
To the Editor Robust and high-quality evidence generation for new drugs and devices benefits many parties. Ensuring that this evidence proves that treatments are beneficial is essential. As our health care system operates like a speeding train with no brakes immediately following US Food and Drug Administration (FDA) approval, reasonable evidence that benefits exceed harms must be obtained before approval.
-
Nov 15, 2024 | 
jamanetwork.com | Ali Abbasi |Lesley H. Curtis |Robert M. Califf
In Reply The letter by Mr Hauser and Dr Redberg commenting on our recent Special Communication1 on the role of payers in evidence generation raises questions regarding the evidence required at the time products are first approved and who should participate in generating evidence after that point. In our article we did not “propose that it is up to payers [instead of FDA] to ensure that benefits exceed harms” as the letter suggests.
-
Nov 13, 2024 | 
mondaq.com | Ali Abbasi
TS
The Sovereign Group
More
Sovereign began in Gibraltar in 1987 and has since grown into one of the largest independent corporate and trust service providers in the world. We currently manage over 20,000 clients that include companies, entrepreneurs, private investors or high net worth individuals and their families – and have assets under administration in excess of US$10 billion.
-
Oct 11, 2024 | 
moviescenecanada.com | Ali Abbasi
Given all the media attention Trump has gotten over the years, especially during his Presidential run and time in the Oval Office, there is little that audiences do not already know about him. Gabriel Sherman’s screenplay does not offer up much new about Trump, jumping through moments of his early life that gives audiences the highlights.
-
Oct 10, 2024 | 
mondaq.com | Ali Abbasi
TS
The Sovereign Group
More
Sovereign began in Gibraltar in 1987 and has since grown into one of the largest independent corporate and trust service providers in the world. We currently manage over 20,000 clients that include companies, entrepreneurs, private investors or high net worth individuals and their families – and have assets under administration in excess of US$10 billion.
-
Oct 4, 2024 | 
cineuropa.org | Ali Abbasi
The images used on this website have been provided by journalists and are believed to be free of rights. However, if you are the owner of an image used on this website and believe that its use infringes on your copyright, please contact us immediately. We will remove the image in question as soon as possible. We have made reasonable efforts to ensure that all images used on this website are used legally and in accordance with copyright laws.
-
Sep 10, 2024 | 
rottentomatoes.com | Ali Abbasi |Sebastian Stan |Jeremy Strong |Maria Bakalova
81% Tomatometer 215 Reviews 84% Popcornmeter 250+ Verified Ratings A young Donald Trump (Sebastian Stan), eager to make his name as a hungry second son of a wealthy family in 1970s New York, comes under the spell of Roy Cohn (Jeremy Strong), the cutthroat attorney who would help create the Donald Trump we know today. Cohn sees in Trump the perfect protégé -- someone with raw ambition, a hunger for success, and a willingness to do whatever it takes to win.
-
Jul 11, 2024 | 
jamanetwork.com | Joelle A. Hallak |Outcomes Research |Ali Abbasi |Currently with
Key PointsQuestion Are Janus kinase inhibitors (JAKis) in autoimmune diseases associated with a reduction in age-related macular degeneration (AMD)? Findings Using MarketScan and Optum administrative claims data (2010-2022), this cohort study compared AMD incidence among 29 586 propensity score–matched patients who received JAKi-based immunotherapy vs non–JAKi-based immunotherapy for autoimmune diseases.
